{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:02:29Z","timestamp":1793109749736,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"the Japanese Society for the Promotion of Science","doi-asserted-by":"crossref","award":["18K15978"],"award-info":[{"award-number":["18K15978"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The advent of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of patients with advanced malignancies. On the other hand, these drugs might cause immune-related adverse events (irAEs) including endocrinopathies and nephropathies. Thyroid dysfunction is one of the most common irAEs. For ICIs-induced nephropathies, most cases are due to tubulointerstitial nephritis, which might require steroid treatment. Here, we report a patient with non-small cell lung cancer treated with ICI who developed increased serum creatinine (s-Cr) levels due to ICIs-induced hypothyroidism.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 57-year-old Asian man with refractory non-small cell lung cancer under ICIs therapy (pembrolizumab, an anti-programmed cell death-1 monoclonal antibody) developed increased s-Cr levels 5 months after the pembrolizumab initiation. His laboratory data, renal biopsy, and Gallium-67 scintigraphy findings denied pembrolizumab-induced tubulointerstitial nephritis. His renal function was correlated with thyroid function. Despite the increase of s-Cr levels, serum cystatin C levels were normal, which could be explained by the hypothyroidism. Levothyroxine treatment improved renal function as well as thyroid function. Then pembrolizumab was resumed, and both his thyroid and renal function remained normal level. Ultimately, we concluded that the increased s-Cr levels were caused by pembrolizumab-induced hypothyroidism.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>All clinicians involved in ICI treatment need to recognize the possible increase in s-Cr levels caused by ICIs-induced hypothyroidism, and we propose monitoring serum cystatin C levels to differentiate ICIs-induced hypothyroidism from tubulointerstitial nephritis before invasive renal biopsies or steroid treatment, which are recommended by the prescribing information for pembrolizumab, are performed.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-020-01775-z","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T15:39:16Z","timestamp":1585669156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Natsumi","family":"Matsuoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishio","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"1775_CR1","volume-title":"Keytruda (pembrolizumab) [prescribing information]","author":"MC Inc","year":"2018","unstructured":"Inc MC. Keytruda (pembrolizumab) [prescribing information]. NJ: Merck & CO Inc; 2018. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf."},{"issue":"2","key":"1775_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45(2):160\u20139.","journal-title":"Am J Nephrol"},{"issue":"10027","key":"1775_CR3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350.","journal-title":"Lancet"},{"issue":"11","key":"1775_CR4","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12(11):2777\u201389.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"1775_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1365-2265.2005.02236.x","volume":"62","author":"JG den Hollander","year":"2005","unstructured":"den Hollander JG, Wulkan RW, Mantel MJ, Berghout A. Correlation between severity of thyroid dysfunction and renal function. Clin Endocrinol. 2005;62(4):423\u20137.","journal-title":"Clin Endocrinol"},{"issue":"9","key":"1775_CR6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S0026-0495(97)90279-1","volume":"46","author":"J Verhelst","year":"1997","unstructured":"Verhelst J, Berwaerts J, Marescau B, Abs R, Neels H, Mahler C, et al. Serum creatine, creatinine, and other guanidino compounds in patients with thyroid dysfunction. Metabolism. 1997;46(9):1063\u20137.","journal-title":"Metabolism"},{"issue":"1","key":"1775_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s12020-019-01903-2","volume":"65","author":"E Sonmez","year":"2019","unstructured":"Sonmez E, Bulur O, Ertugrul DT, Sahin K, Beyan E, Dal K. Hyperthyroidism influences renal function. Endocrine. 2019;65(1):144\u20138.","journal-title":"Endocrine"},{"issue":"2","key":"1775_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4103\/2230-8210.93737","volume":"16","author":"G Basu","year":"2012","unstructured":"Basu G, Mohapatra A. Interactions between thyroid disorders and kidney disease. Indian J Endocrinol Metab. 2012;16(2):204\u201313.","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"1775_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/archinte.159.1.79","volume":"159","author":"SH Kreisman","year":"1999","unstructured":"Kreisman SH, Hennessey JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med. 1999;159(1):79\u201382.","journal-title":"Arch Intern Med"},{"issue":"2","key":"1775_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1530\/eje.1.02093","volume":"154","author":"F Vargas","year":"2006","unstructured":"Vargas F, Moreno JM, Rodriguez-Gomez I, Wangensteen R, Osuna A, Alvarez-Guerra M, et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol. 2006;154(2):197\u2013212.","journal-title":"Eur J Endocrinol"},{"issue":"2 Pt 2","key":"1775_CR11","first-page":"H283","volume":"252","author":"HK Hammond","year":"1987","unstructured":"Hammond HK, White FC, Buxton IL, Saltzstein P, Brunton LL, Longhurst JC. Increased myocardial beta-receptors and adrenergic responses in hyperthyroid pigs. Am J Phys. 1987;252(2 Pt 2):H283\u201390.","journal-title":"Am J Phys"},{"issue":"4","key":"1775_CR12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0022-5223(94)70292-6","volume":"108","author":"JD Walker","year":"1994","unstructured":"Walker JD, Crawford FA, Kato S, Spinale FG. The novel effects of 3,5,3\u2032-triiodo-L-thyronine on myocyte contractile function and beta-adrenergic responsiveness in dilated cardiomyopathy. J Thorac Cardiovasc Surg. 1994;108(4):672\u20139.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"1775_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1475-097X.1986.tb00066.x","volume":"6","author":"F Celsing","year":"1986","unstructured":"Celsing F, Blomstrand E, Melichna J, Terrados N, Clausen N, Lins PE, et al. Effect of hyperthyroidism on fibre-type composition, fibre area, glycogen content and enzyme activity in human skeletal muscle. Clin Physiol. 1986;6(2):171\u201381.","journal-title":"Clin Physiol"},{"issue":"11","key":"1775_CR14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1055\/s-2007-979105","volume":"29","author":"BJ Asmah","year":"1997","unstructured":"Asmah BJ, Wan Nazaimoon WM, Norazmi K, Tan TT, Khalid BA. Plasma renin and aldosterone in thyroid diseases. Horm Metab Res. 1997;29(11):580\u20133.","journal-title":"Horm Metab Res"},{"issue":"5","key":"1775_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.5414\/CNP64391","volume":"64","author":"S Kursat","year":"2005","unstructured":"Kursat S, Alici T, Colak HB. A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism. Clin Nephrol. 2005;64(5):391\u20133.","journal-title":"Clin Nephrol"},{"issue":"6","key":"1775_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1046\/j.1365-2265.1999.00861.x","volume":"51","author":"H Norrelund","year":"1999","unstructured":"Norrelund H, Hove KY, Brems-Dalgaard E, Jurik AG, Nielsen LP, Nielsen S, et al. Muscle mass and function in thyrotoxic patients before and during medical treatment. Clin Endocrinol. 1999;51(6):693\u20139.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"1775_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1172\/JCI101717","volume":"25","author":"L Wilkins","year":"1946","unstructured":"Wilkins L, Fleischmann W. Effects of thyroid on Creatine metabolism with a discussion of the mechanism of storage and excretion of Creatine bodies. J Clin Invest. 1946;25(3):360\u201377.","journal-title":"J Clin Invest"},{"issue":"1","key":"1775_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000329354","volume":"35","author":"M Kimmel","year":"2012","unstructured":"Kimmel M, Braun N, Alscher MD. Influence of thyroid function on different kidney function tests. Kidney Blood Press Res. 2012;35(1):9\u201317.","journal-title":"Kidney Blood Press Res"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-020-01775-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T23:08:15Z","timestamp":1617145695000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01775-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1775"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01775-z","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]},"assertion":[{"value":"1 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s wife for publication of this Case report and any accompanying images, due to the death of the patient after the oral agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}